Enanta Pharmaceuticals, Inc. (ENTA)
13.60
-0.20
(-1.45%)
USD |
NASDAQ |
Aug 28, 16:00
13.58
-0.02
(-0.11%)
After-Hours: 20:00
Enanta Pharmaceuticals Net Income (Quarterly) : -19.50M for June 30, 2026
Net Income (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -19.50M |
| March 31, 2026 | -13.09M |
| December 31, 2025 | -11.94M |
| September 30, 2025 | -18.70M |
| June 30, 2025 | -18.26M |
| March 31, 2025 | -22.64M |
| December 31, 2024 | -22.29M |
| September 30, 2024 | -28.82M |
| June 30, 2024 | -22.66M |
| March 31, 2024 | -31.16M |
| December 31, 2023 | -33.41M |
| September 30, 2023 | -28.11M |
| June 30, 2023 | -39.06M |
| March 31, 2023 | -37.66M |
| December 31, 2022 | -28.99M |
| September 30, 2022 | -26.35M |
| June 30, 2022 | -31.70M |
| March 31, 2022 | -33.59M |
| December 31, 2021 | -30.12M |
| September 30, 2021 | -24.60M |
| June 30, 2021 | -24.02M |
| March 31, 2021 | -22.04M |
| December 31, 2020 | -8.328M |
| September 30, 2020 | -29.34M |
| June 30, 2020 | -14.26M |
| Date | Value |
|---|---|
| March 31, 2020 | -6.005M |
| December 31, 2019 | 13.44M |
| September 30, 2019 | 9.191M |
| June 30, 2019 | 7.036M |
| March 31, 2019 | 4.145M |
| December 31, 2018 | 26.01M |
| September 30, 2018 | 27.42M |
| June 30, 2018 | 20.29M |
| March 31, 2018 | 12.56M |
| December 31, 2017 | 11.69M |
| September 30, 2017 | 36.51M |
| June 30, 2017 | -8.426M |
| March 31, 2017 | -5.392M |
| December 31, 2016 | -4.98M |
| September 30, 2016 | -1.802M |
| June 30, 2016 | -1.076M |
| March 31, 2016 | -1.645M |
| December 31, 2015 | 26.19M |
| September 30, 2015 | 5.812M |
| June 30, 2015 | 2.418M |
| March 31, 2015 | 28.75M |
| December 31, 2014 | 42.01M |
| September 30, 2014 | -5.042M |
| June 30, 2014 | 50.05M |
| March 31, 2014 | -5.203M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Perspective Therapeutics, Inc. | -26.98M |
| AbbVie, Inc. | 3.604B |
| Coherus Oncology, Inc. | -33.35M |
| BridgeBio Pharma, Inc. | -155.89M |
| RenovoRx, Inc. | -2.911M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 14.36M |
| Total Expenses (Quarterly) | 33.86M |
| EPS Diluted (Quarterly) | -0.6704 |
| Enterprise Value | 388.57M |
| Gross Profit Margin (Quarterly) | 91.75% |
| Profit Margin (Quarterly) | -135.8% |
| Earnings Yield | -17.73% |
| Normalized Earnings Yield | -17.73 |